GO
Loading...

GlaxoSmithKline PLC

More

  • Dec 23- The U.S. Department of Health and Human Services awarded contracts worth a total of about $43 million to NewLink Genetics Corp and GlaxoSmithKline Plc for faster development of two Ebola vaccines. Under a $30 million contract, NewLink's unit BioProtection Systems Corp will conduct clinical trials to determine the lowest dose at which its vaccine...

  • Dec 22- The U.S. Food and Drug Administration approved Biocryst Pharmaceuticals Inc's intravenous flu drug, sending the company's shares up nearly 10 percent in premarket trading. The single-dose drug is for adults who have acute uncomplicated influenza and may be unable to swallow pills, such as Gilead Sciences Inc's Tamiflu, or inhale GlaxoSmithKline...

  • GENEVA, Dec 19- Trials of GlaxoSmithKline's experimental Ebola vaccine are likely to move to a second phase in February, later than previously suggested, after a meeting of national regulators said they needed more information. Countries where the trials are planned-- Cameroon, Ghana, Mali, Nigeria and Senegal-- should receive and review the additional...

  • *Shares in GSK partner Agenus jump 10 percent. LONDON, Dec 18- An experimental shingles vaccine from GlaxoSmithKline has produced impressive results in a late-stage study, giving the group's expanding vaccine unit a potential $1 billion boost. The data suggests the British company's new shot could be a strong competitor for Merck& Co's established vaccine...

  • LONDON, Dec 18- Shareholders in British drugmaker GlaxoSmithKline have approved a planned deal with Switzerland's Novartis, which will see the two pharmaceutical groups trade more than $20 billion of assets. The transaction, which includes GSK buying Novartis' vaccines business, Novartis purchasing GSK's cancer drugs, and the two groups tying up in consumer...

  • LONDON, Dec 18- An experimental vaccine against shingles from GlaxoSmithKline met its goal in a late-stage study, in a boost for the company's vaccine unit, which is expanding part of its overall healthcare business. The adjuvant includes a component from U.S. biotech firm Agenus, which is entitled to royalties on any future sales. Merck& Co already sells another...

  • Dec 12- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers. The deal stirred speculation that developers such as Cempra could also be takeover targets. I know a lot of other biotechs are, " Cempra Chief Executive Prabha Fernandes said in an...

  • LONDON/ GENEVA, Dec 11- GAVI, the global vaccines alliance, said on Thursday it was committing up to $300 million to buy Ebola vaccines, as one experimental shot hit a snag in a Swiss clinical trial after some subjects reported joint pains. GAVI, which is funded by governments and the Bill& Melinda Gates Foundation, said it was ready to begin procurement as soon as the...

  • LONDON, Dec 11- GAVI, the global vaccines alliance, said on Thursday it was committing up to $300 million to buy Ebola vaccines and was ready to begin procurement as soon as the World Health Organization recommends one for use. Clinical trials with experimental shots are now underway as experts race to contain an epidemic that has killed more than 6,000 people in...

  • US STOCKS-Futures edge lower after volatile session Wednesday, 10 Dec 2014 | 8:36 AM ET

    *Costco, Toll Brothers post quarterly results. NEW YORK, Dec 10- U.S. stock index futures edged lower on Wednesday, a day after stocks staged an intraday rally to erase a decline of nearly 1.3 percent and end nearly flat. Oil prices have been under pressure from the dollar's strength and OPEC's decision against an output cut, with Brent down more than 40 percent from...

  • LONDON, Dec 10- Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development increasing for the first time since 2010.. So far this year the U.S. Food and Drug Administration, which acts as gatekeeper to the world's biggest market, has approved 35 new products, up from 27 in the whole of 2013...

  • CHICAGO, Dec 9- The U.S. Department of Health and Human Services on Tuesday offered liability protections to drugmakers rushing to develop Ebola vaccines and urged other countries to follow suit. Health and Human Services Secretary Sylvia Burwell made the announcement as part of the Public Readiness and Emergency Preparedness Act in a move aimed at...

  • The sukuk from the International Finance Facility for Immunization Co, for which the World Bank acts as treasury manager, is a break from the predominantly commercial nature of most Islamic finance transactions. The deal is part of World Bank efforts to adapt sukuk for use in a variety of ethical pursuits, including advising the Dubai government on a funding...

  • LONDON, Dec 4- GlaxoSmithKline said on Thursday it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers. A spokesman for GSK, which was being advised on the disposal by Lazard, declined to give any more details. Bidders, who had been hoping to clinch a deal before the end of the year,...

  • UPDATE 1-GlaxoSmithKline abandons sale of older drugs Thursday, 4 Dec 2014 | 12:03 PM ET

    LONDON, Dec 4- GlaxoSmithKline said on Thursday it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers. A spokesman for GSK, which was being advised on the disposal by Lazard, declined to give any more details. People familiar with the situation said last month that several private...

  • GlaxoSmithKline abandons sale of older drugs Thursday, 4 Dec 2014 | 11:28 AM ET

    LONDON, Dec 4- GlaxoSmithKline said on Thursday it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers.

  • Ebola booster vaccine starts first trials in Oxford Thursday, 4 Dec 2014 | 4:25 AM ET

    LONDON, Dec 4- Scientists at Oxford University have launched the first clinical tests of a new Ebola vaccine approach, using a booster developed by Denmark's Bavarian Nordic that may improve the effects of a shot from GlaxoSmithKline. Thirty healthy volunteers in Britain who have already received the experimental Ebola vaccine being developed by GSK and the...

  • Many posts going at North Carolina research site. LONDON, Dec 3- GlaxoSmithKline said on Wednesday it would shed "several hundred" U.S. commercial jobs and a similar number of research positions as it restructures operations in its biggest market, where drug sales are flagging. Many of the jobs lost will be from GSK's Research Triangle Park site in North Carolina...

  • LONDON, Dec 3- GlaxoSmithKline confirmed on Wednesday it would shed several hundred U.S. commercial jobs and a similar number of research positions as it restructures operations in its biggest market, where drug sales are flagging. Many of the jobs lost will be from GSK's Research Triangle Park site in North Carolina as drug research is consolidated in...

  • GSK to ax US jobs in major cost cuts: Sources Monday, 1 Dec 2014 | 2:11 AM ET

    GSK will ax hundreds of U.S. jobs in its biggest market as the drugmaker starts implementing a major cost-saving program.